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 The method to identify and isolate the proteins is one of the keys to the immunoassay 
production. However, currently there is no effective way to isolate the protein not only because 
of limited number of technologies for protein detection but also the existing technologies have 
downfall of low sensitivity for protein detection and the secreted protein cross-reactivity. The 
present paper demonstrates the isolation and collection ability of the Janus particle. The study 
demonstrates the creation of Janus particle with one side of the particle targets and binds plasma 
cells while the other side contains protein G that collects specific antibodies that are secreted. 
Experiments were conducted to determine the ability of 2 μm and 4 μm size Janus Particle. 
Moreover, the study was carried out with hybridoma cells to determine whether the Janus 






Proteins are key modulators for various functions in the human body. Cytokines, small 
proteins secreted from both immune and non-immune cells, are vital to cell signaling and are 
closely associated with immune system responses such as inflammation and central sensitization 
[1, 2]. The measurement of cytokine activities is extremely important because elevated or 
depressed concentration of cytokines are associated with inflammation or disease progression. 
Monitoring cytokine concentrations in body fluids can help to understand the disease 
pathogenesis and effects of treatment, and cytokine molecules can be utilized in several clinical 
applications such as cancer therapy and autoimmune disease treatments [3,4]. Antibodies, 
proteins secreted by plasma B cells in response to antigens, are key components of the immune 
system and are utilized in vaccine production, antibody therapy, disease diagnosis, and a wide 
variety of other biomedical applications. Isolating and purifying plasma B cells and their secreted 
antibodies specific to a target antigen is extremely important for the development of these 
applications, as well as analysis of different antibody molecules can provide further insight into 
how the immune system responds to different antigens. 
Various techniques to quantify cytokines, such as immunoassay, ELISA, enzyme-linked 
immunosorbent spot (ELIspot), antibody array assay, and bead-based assay, have been used, but 
there are common challenges that undermine their effectiveness. Cytokines are often secreted 
into the extracellular environment in pM concentrations, and current detection techniques are not 
sensitive enough to detect such low concentrations accurately. In addition, interference from 
other heterophilic antibodies, rheumatoid factors, and cytokine-binding proteins creates noise in 
the measurements, and the dynamic process of cytokine secretion prevents accuracy and 
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reproducibility. ELISA produces the most reliable data but is time consuming (6 hours) and 
usually requires a relatively large sample volume (100 µL) [5].  
  The most standard technique to isolate antigen-specific B cells is fluorescence-activated 
cell sorting (FACS) after labeling surface antibodies with fluorescent antigen [6]. However, 
identifying and isolating plasma cells is an ambitious proposal because plasma cells lack surface 
antibodies and only constitute a tiny percentage of the whole blood cells [7]. A majority of 
diagnostic and therapeutic antibodies are produced using the mouse-human hybridoma technique 
which immortalizes antibody secreting cells and allows for the production of antibodies for a 
prolonged time period: however, this method is not suitable for human use and has created many 
controversies related to animal welfare [8, 9]. Therefore, to obtain antibodies for antigen that are 
specific for humans, it is best to collect antibodies directly from plasma B cells. 
 In the past 15 years, several advancements have been made for the detection and the 
quantification of cytokines and antibodies using magnetic beads, nanomaterials, antigen 
stimulation, and multiplex bead assays [5,10]. Each advancement aims to enhance sensitivity, 
selectivity, and/or simplicity, but all hold disadvantages such as high cost, high complexity, and 
limited availability of resources. High complexity compromises the survivability of cells, and 
high cost and limited availability prevents commercial use. Therefore, the development of a 
simpler yet effective protein detection and collection technique is pivotal for the efficient 
production of proteins and subsequent analysis, reproduction, and therapy. 
This study proposes the utilization of bifunctional microparticles for the isolation of 
specific plasma B cells. Janus particles, particles with two physically and chemically distinct 
hemispheres, are engineered such that one side binds to antigen-specific plasma B cells and the 
other collects the secreted antibodies simultaneously. Anti-CD44 antibody conjugated on one 
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hemisphere targets the surface marker CD44 on plasma B cells, while protein G, which has been 
proven to have high antibody affinity, captures and immobilizes the antibodies [11]. The 
isolation efficiency of Janus particles is compared to that of mixed particles, which are protein G 
coated silica particles bifunctionalized with the conjugation of anti-CD44 antibodies without any 
spatial segregation. The team also investigates the relationship between particle size and the 
antibody collection efficiency to identify the best particle size for optimized cell isolation. Fewer 
steps involved in the proposed technique will enhance the survival rate of plasma cells and 
increase the isolation efficiency. Moreover, optimization of this technique will establish a new 
mechanism to identify and sort large numbers of specific plasma cells for further applications. 
The sorted plasma cells can be immortalized for mass production of antibodies, enabling the 
development of new antibodies for prevention and/or treatment of infectious diseases. 
Bifunctional microparticles hold many possibilities as the new novel cell isolation tool, and a 






Methods and Materials 
Material 
Silica microspheres with diameters of 4μm carboxylated polystyrene microspheres were 
purchased from Bangs Laboratories (Fishers, IN). Coupling reagents, including (3-
Aminopropyl)triethoxysilane (APTES), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDAC), acetone, phosphate buffered saline (PBS), PolyLink Wash/Storage Buffer, PolyLink 
Coupling Buffer, Dulbecco's Modified Eagle's Medium (DMEM), Iscove’s Modified Dulbecco’s 
Medium (IMDM), gentamicin, penicillin/streptomycin, L-glutamine 200mM, 1% sodium 
pyruvate, concanavalin A Alexa Fluor 488 were purchased from Sigma-Aldrich (St. Louis, MO), 
fetal bovine serum from Atlanta Biologicals (Atlanta, GA). Bovine serum albumin (BSA) were 
purchased from Sigma-Aldrich (St. Louis, MO). Thiol-poly(ethylene glycol)-biotin, a 
heterobifunctional PEG derivative, was purchased from Nanocs (New York, NY). Human Bcl6 
peptide were purchase from Abcam (Cambridge, UK). APC Anti-mouse/human Anti-CD44 
antibody from Biolegend (San Diego, CA). Lightning-Link® Streptavidin from expedeon (San 
Diego, CA). Protein G was purchased from Protein Specialists (East Brunswick, NJ).  
Method 
Cell Culturing 
 TIB 147 cells from ATCC (Manassas, VA) and BCL6 hybridomas from Iowa University 
(Iowa University Hybridoma Bank, Iowa City, IA) were used to test the particle’s ability to 
collect and identify specific antibodies, anti-concanavalin A and anti-BCL6, from cell culture 
media and supernatants. Both cells were cultured at a concentration of 106 cells/mL and 
incubated in humified incubator at 37°C with 5%. BCL6 hybridoma was cultured using IMDM 
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complete media with 20% fetal bovine serum, 1% L-glutamine 200mM, 1% sodium pyruvate 
100Mm, 0.1% gentamicin 50mg/ml, and 0.1% penicillin/streptomycin. 
 
Preparation of Janus Particle 
 The protocol to create the Janus particle was modified based on proposed mechanism 
by Tang et al [12]. The 2 and 4μm silica particles are washed multiple times using 100% 
ethanol in 1:10  ratio of particle stock solution to ethanol. After two wash, the particle is 
kept in the ethanol solution in chosen ratio for approximately 5minutes then 8 μL was 
depostied onto the glass slide, which was moved onto orbital rotator at 200rpm to completely 
dry. Then, the tape is placed in opposite side of the deposition layer, and the slides were 
coated with a layer of gold following a titanium adhesion layer using a metal evaporation 
process (CHA E-Beam Evaporator). The thickness of titanium and gold deposition was in 
0.1 kÅm, 0.1kÅ and 0.5kÅ and 1 kÅ with a rate of 1 Å/s, respectively, for 2μm and 4 μm. After 
the gold deposition, the slide was placed into 50 mL tube filled with deionized water and 
sonicated for 5 minutes. After the particle is collected from the tube, the gold hemisphere is 
modified using thiol-PEG-biotin, and silica side with APTES and the carboxylated 







Janus particle with two hemispheres targeting the cell 
                 
Figure 2. The Visual representation of Janus Particle (on left) and the Confocal Laser 
Microscopy image of Janus Particle of 3.98 µm targeting the BCL6 hybridoma cells 
(on right).  
The visual representation on the Figure 2 (left) represents formation of Janus particle 
that is used to target the specific cell, BCL6 hybridoma cell(Figure 2 right). The Figure 2 
image was used to confirm that Janus particle has two distinct hemispheres and demonstrate 
that Janus particle is accurately produced as desired with both sides precisely functionalized 
with bifunctionalized surface spatial segregation.  The black slide on the image represents 
the gold hemisphere and white slide correspond to silica side. The gold hemisphere targets 
the specific cells and silica hemisphere collect the antibodies secreted by the cells.  The 




Figure 3. Accuracy, Specificity, and Sensitivity of the Mixed particles, Orange bar 
representing 4μm and Blue bar representing 2μm based on the result collected based on 
confocal analysis and flow cytometry result.  
Based on Figure 3, the percentages of all three categories for both 2μm and 4μm Janus 
Particles are all above the 85% indicating that within the mixture of hybridoma cells, the 
bifunctional particles are able to detect the cell that secretes a specific antibody with the high 
sensitivity, specificity, and accuracy. However, in comparison, the particle of 4μm demonstrated 

















 The Janus demonstrated the ability to isolate specific hybridoma cells and to collect 
secreted antibodies. These properties were confirmed using fluorescent dye on cells as well as 
labeling on secreted antibodies. The binding properties was augmented based on the anti-CD 
conjugation resulted in higher specificity on isolating the cells secreting the antibodies.  
Both 2μm and 4μm Janus Particles showed the ability in isolating single cell and collecting 
the antibody, they showed high ability in different aspects with all the percentage above 85%. 
Comparing the ability of 2μm, 4μm Janus particle demonstrated greater ability in overall all the 
aspects in terms of accuracy, specificity, and sensitivity, which indicates that 4μm Janus particle 
demonstrated better both targeting and collection ability as well as the localization of antibody 
collection. The 4μm Janus particle with greater surface area of distinct hemisphere could enhance the 
binding to cell and collection of antibodies. The Janus particle is showing great potential as a 
single cell sensor and protein collector.  
Conclusion 
 The Janus particle that demonstrates promising results as a novel biotechnology 
application to study various protein secreting cells and to collect the secretions. A secreted 
products reagent has potential advantage for biomedical related research in terms of isolation of 
rare cells or genetic variants of cytokine-secreting lymphocytes, or single-cell analyses of 
exocytosis, hormones, or viruses. Moreover, these collected proteins and antibodies could be 
potentially applicable to enhance currently existing therapies by selecting only specific cells. To 
further enhance the study and investigate greater use of the bifunctional particles in aspect of 
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